BriaCell Stock Is Trading Higher After Encouraging Bria-IMT Data At AACR Annual Meeting - BriaCell Therapeutics (NASDAQ:BCTX)

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced the presentation of results from clinical studies evaluating its lead product candidate, Bria-IMT, at the American Association for Cancer Research (AACR) Annual Meeting 2021.
The findings indicate disease control in advanced breast cancer patients, including stable disease (SD), partial responses (PR), or complete responses (CR).
The Bria-IMT regimen with or without checkpoint inhibitors can induce an effective immune response and disease control in heavily pre-treated advanced breast cancer patients.
Delayed-Type Hypersensitivity (DTH) to Bria-IMT analysis identified a group with significantly higher rates of disease control and progression-free survival (8 months) in both monotherapy and combination therapy studies suggesting a robust immune response is predictive of clinical benefit in these patients.
The highest levels of disease control and progression-free survival were observed in patients who matched Bria-IMT at 2 or more HLA alleles in the monotherapy study but not in the combination therapy with Bria-OTS, off-the-shelf personalized immunotherapy for advanced breast cancer.
Patients with Grade I/II tumors (median of 8 prior therapy regimens) were more likely to respond with the disease control (67%) and longer progression-free survival.
The response was evident in the patients in the combination therapy study suggesting synergistic effects of checkpoint inhibitors combined with the Bria-IMT regimen.
BriaCell is currently conducting a Phase 1/2a clinical trial of Bria-IMT in a Combination Study with immune checkpoint inhibitors.
Price Action: BCTX shares are up 2.1% at $5.32 during the premarket session on the last check Monday.

BCTXBriaCell Therapeutics Corp

$4.03-0.98%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.